On April 20, 2026, PLUS Therapeutics, Inc. confirmed it regained compliance with Nasdaq's minimum bid price requirement following a one-for-twenty-five reverse stock split effective April 2, 2026, marking a significant event for the company. The Notification Letter from Nasdaq signifies a positive development for investors.